Medical Health Cluster

Safety

Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine

BACKGROUND Active immunization with the BNT162b2 vaccine (Pfizer–BioNTech) has been a critical mitigation tool against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection during the coronavirus disease 2019 (Covid-19) pandemic. In light of reports of waning protection occurring 6 months after the primary two-dose vaccine series, data are needed on […]

Read More